



In vitro Evaluation of the Effects of Fluconazole and Nano-Fluconazole on *Aspergillus flavus* and *A. fumigatus* Isolates

Mohammad Reza Sarrafha,¹ Seyed Jamal Hashemi,^{2*} Sasan Rezaei,² and Mansour Bayat¹

¹Department of Microbiology, Science and Research Branch, Islamic Azad University, Tehran, IR Iran

²Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Seyed Jamal Hashemi, Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran. Tel: +98-9121009141, E-mail: sjhashemi@tums.ac.ir

Received 2017 July 09; Revised 2018 April 30; Accepted 2018 May 01.

Abstract

Background: Increasing azole resistance among *Aspergillus* strains was observed over the last decade. For this reason, viable alternatives for the current medicines are required.

Objectives: The current study aimed at producing fluconazole-loaded liposomal nanoparticles and comparing *in vitro* antifungal activity of fluconazole and nano-fluconazole on *Aspergillus flavus* and *A. fumigatus* species isolated from patients and poultry.

Methods: Fifty isolates of *A. flavus* and *A. fumigatus* were collected from visceral and superficial fungal lesions of humans as well as pulmonary fungal infection of poultry. Liposomal nanoparticles were prepared by thin-film hydration method, using soybean lecithin, cholesterol, and fluconazole in a ratio of 10:1:1. The nanoparticles were analyzed in terms of size, zeta potential, and morphology. Antifungal susceptibility testing was carried out to examine and evaluate the minimum inhibitory concentration (MIC) of fluconazole and nano-fluconazole against *Aspergillus* species by the standard method of broth microdilution as described in CLSI (the clinical and laboratory standards institute)-M38A2.

Results: The particle size of liposomes containing fluconazole was 88.9 ± 12.1 nm and its zeta potential was -20.12 ± 1.88 mv. Nano-liposomes containing fluconazole significantly reduced the MIC against *A. flavus* ($P = 0.0005$) and *A. fumigatus* ($P < 0.0001$).

Conclusions: The results of the current *in vitro* study showed that nano-fluconazole has better antifungal effects than the common form of drug on *A. flavus* and *A. fumigatus* species. The current study showed the antifungal activity of nano-drugs.

Keywords: Antifungal Agent, Fluconazole, *Aspergillus flavus*, *Aspergillus fumigatus*

1. Background

Invasive fungal infections, especially those caused by filamentous fungi, increased particularly among high-risk patients such as allogeneic stem-cell transplant recipients (1). *Aspergillus* species are opportunistic fungi causing both allergic and invasive fungal infections. They are also important causes of life-threatening infections in immunocompromised patients (2, 3). In humans, *Aspergillus fumigatus* is the most common opportunistic fungal pathogen, remarkably among immunocompromised hosts (4). After *A. fumigatus*, *A. flavus* is the second leading cause of invasive aspergillosis, and is the most common cause of superficial infections (5). Aspergillosis is the most common opportunistic mycotic infection of the respiratory tract in birds that causes high morbidity and mortality, thus resulting in significant economic losses, especially in poultry (6). Other *Aspergillus* species may also be isolated from cases of aspergillosis in commercial poultry, but much less

frequently than *A. fumigatus* and *A. flavus* (4).

Azoles are antifungal agents that are widely used in both agricultural and public health settings because of their excellent activity against pathogenic fungi (7). Reports of azole resistance are emerging, and resistance is now recognized as a cause of treatment failure (8). Azole resistance in *A. fumigatus* is a global concern and an important factor in treatment failure (9). Modification and overexpression of the azole target enzyme 14- α steroldemethylase (*cyp51A*) or are the main mechanisms involved in *A. fumigatus* azole-resistance (10). Liposomes can be the carrier for both hydrophilic and hydrophobic drugs (11).

Liposomes are relatively non-toxic and biodegradable. Therefore, they have a wide range of biomedical applications (12). The small size of lipid nanoparticles increases their access to the tissue, thereby enhances the influence of encapsulated drugs (13). Due to the increased prevalence of aspergillosis and increased resistance to common drugs and their side effects, an appropriate alternative to such

medicines is essential. In the current *in vitro* study, the effect of nano-liposomes containing fluconazole on *A. flavus* and *A. fumigatus* were investigated by susceptibility testing.

2. Objectives

The current *in vitro* study aimed at producing fluconazole-loaded liposomal nanoparticles and comparing the antifungal activity of fluconazole and nano-fluconazole against *A. flavus* and *A. fumigatus* species isolated from humans and poultry. For this purpose, the minimum inhibitory concentration (MIC) of fluconazole and nano-fluconazole against *Aspergillus* spp. were assessed and the results were compared.

3. Methods

3.1. Ethics Statement

The study was approved by the ethics committee of Tehran University of Medical Science (IR.TUMS.SPH.Rec1395.1339).

3.2. Fungal Isolates

Fifty *A. flavus* and *A. fumigatus* species were isolated from visceral and superficial lesions of humans and pulmonary fungal infections of poultry. Twenty species isolated from superficial fungal (nails and ear discharges) and visceral (BAL, sinus discharge, and sputum) lesions in patients referred to the mycology department of school of Public Health, Tehran University, and thirty species isolated from nodules or white plaques of lungs in dead poultry with respiratory symptoms were collected from different poultry farms in Qazvin province, Iran. Diagnosis of aspergillosis was performed by direct examination and culture on SDA. The isolated species were identified using mycological techniques such as macroscopic examination to study the morphology of colonies, microscopic methods to study the morphology of conidia, and sequencing of beta-tubulin genes to confirm the results.

3.3. Preparation of Fluconazole and Nano-Fluconazole, and Analyzing Data

3.3.1. Preparation of Fluconazole and Nano-Fluconazole

Crude powder of fluconazole (Sigma-Aldrich, Steinheim, Germany) was purchased from Sigma Company. Liposomal formulation of fluconazole was prepared by thin-film hydration method (14). To prepare liposomes, lecithin, cholesterol, and fluconazole were used in a ratio of 10:1:1. A thin film was formed by dissolving the two substances at 5.12 mg/mL in an organic solvent mixture comprising

chloroform-methanol (1:1) containing fluconazole. The final concentration of 5,120 $\mu\text{g/mL}$ was prepared. The thin film was dissolved in 100 mL of distilled water by incubating the mixture in water bath for 30 minutes at 55 - 60°C. Then, the liposome mixture was sonicated by a probe-type ultrasonication for 15 minutes. The mixture was immediately transferred to laboratory and used to assess MIC. Blank liposomal formulation was prepared in the same manner, without adding fluconazole.

3.3.2. Measurement of Zeta Potential and Particle Size of Blank/Fluconazole-Loaded Nano-Liposomes

Zeta potential was measured by a Zetasizer device, based on laser light scattering. Particle size distribution in the device was evaluated based on PDI (poly-dispersity index).

3.3.3. Nanoparticle Structure

To examine nanoparticles structure, a scanning electron microscope (SEM) was used. A small quantity of sample was placed on a glass surface in 1×1 cm. It was then placed inside an incubator at 37°C until the sample was completely dried. Then, the particles were coated with gold. Magnifications of X20,000 and X40,000 were used.

3.4. Antifungal Susceptibility Testing

3.4.1. Preparation of Stock Solution from Fluconazole and Nano-Fluconazole

Crude powder of fluconazole was dissolved in distilled water. A stock solution containing 5,120 $\mu\text{g/mL}$ of fluconazole was prepared based on the protocol (15). For comparison, the same concentration of nano-fluconazole was used.

3.4.2. Antifungal Susceptibility Testing with Broth Microdilution Standard Method

In the current study, the antifungal susceptibility test was performed using broth microdilution standard method based on clinical and laboratory standards institute (CLSI) M38-A2 document to assess and evaluate MIC of fluconazole and nano-fluconazole against *Aspergillus* species; *Candida krusei* ATCC 6258 was used as standard quality control (15). In order to dilute the drugs stock solution, the RPMI (Roswell Park Memorial Institute) 1,640 medium (Sigma Chemical Co.) buffered to pH 7.0 with morpholinepropanesulfonic acid (MOPS; 0.165 M) (Sigma) and L-glutamine without bicarbonate were used. Final concentrations of fluconazole and nano-fluconazole ranged 1 - 512 $\mu\text{g/mL}$. According to standard protocol, the drugs in final concentrations were pipetted into the wells of 96-well microplates. Then, the fungal suspension prepared according to CLSI M38-A2 protocol containing 0.4×10^4 - 5×10^4 CFU/mL fungal cells was added.

The 11th well was chosen as a negative control containing RPMI-1640 medium, but lacking the drugs and the fungus. The 12th well was taken as a positive control containing RPMI-1640 medium plus fungal suspension, but lacking the drugs. After gentle mixing, microplates were incubated for 48 hours at 35°C. All tests were performed in triplicate. After 48 hours of incubation, the microplates were examined to determine MIC. The MICs of fluconazole were determined visually. To ensure the inhibition of fungal growth by nano-liposome particles, blank nano-liposome (without drug) was used in the current study, and no anti-fungal growth evidence was observed.

3.5. Statistical Analysis

According to the obtained data, t test was used to compare the groups ($P < 0.05$).

4. Results

A total of 50 clinically isolated *A. flavus* ($n = 25$) and *A. fumigatus* ($n = 25$) species were collected (Table 1).

Table 1. Clinical Specimens and the Number of *A. flavus* and *A. fumigatus* Isolates

Clinical Specimen	No. of <i>A. fumigatus</i> Isolates	No. of <i>A. flavus</i> Isolates
BAL	3	4
Sputum	0	1
Draining sinuses	0	1
Ear discharge	1	2
Nail	3	5
Lung poultry	18	12
Total	25	25

4.1. Zeta Potential and Particle Size of Fluconazole-Loaded Nano-Liposomes

The particle size (88.9 ± 12.1 nm) and zeta potential (-20.12 ± 1.88 mv) of fluconazole-loaded liposomes are shown in Figures 1 and 2.

4.2. SEM Results of Fluconazole-Loaded Nano-Liposomes

Figure 3 shows the particle size distribution of fluconazole-loaded nano-liposomes. Figure 4 shows a greater magnification for a better view of the structure and spherical shape of fluconazole-loaded nano-liposomes. According to the results of SEM, the prepared particles were in the particle size range obtained by a Nano Zetasizer.




Figure 1. Curve of Particle Size Distribution of Fluconazole-loaded Liposomes




Figure 2. Curve of Zeta Potential of Fluconazole-loaded Liposomes




Figure 3. Image of nanoparticles with lower magnification

4.3. Results of Antifungal Susceptibility Testing

Table 2 shows the results of *in vitro* susceptibility testing for fluconazole against *A. flavus* and *A. fumigatus* isolates and comparison of the results with those of fluconazole-loaded liposomal nanoparticles. According to




Figure 4. Image of nanoparticles with greater magnification

the table, the MIC₅₀ of fluconazole and fluconazole-loaded nano-liposomes against *A. flavus* are 128 and 32 µg/mL, respectively. In addition, the MIC₅₀ of fluconazole and fluconazole-loaded nano-liposome against *A. fumigatus* are 128 and 64 µg/mL, respectively. Statistical analyses showed that fluconazole-loaded nano-liposome could significantly reduce the MIC against *A. flavus* (P = 0.0005) and *A. fumigatus* (P < 0.0001).

Figure 5 shows that the mean ± standard error (SEM) of MIC of fluconazole and fluconazole-loaded nano-liposome against *A. flavus* are 119.7 ± 17.68 and 47.04 ± 8.16 µg/mL, respectively. Furthermore, the MIC of fluconazole and fluconazole-loaded nano-liposome against *A. fumigatus* are 174.1 ± 12.54 and 71.68 ± 6.98 µg/mL, respectively; in addition, data had normal distribution.




Figure 5. The mean MIC of fluconazole and fluconazole-loaded nano-liposome against *A. flavus* and *A. fumigatus*

5. Discussion

In the present study, results showed that fluconazole-loaded nano-liposomes were more effective than the common form of fluconazole regarding the removal of *Aspergillus* species. Using nano technology could possibly change the properties of the substances. Zeta potential is an important criterion for the stability of a colloidal system, and a minimum ZP of ± 20 reported by different studies is desirable (16, 17). Cholesterol was used to improve stability because cholesterol can increase zeta potential (18). Zeta potential and particle size have a major effect on various properties of nano-drugs (19). The main objective of the current study was to obtain an ideal formulation in terms of particle size and encapsulation to evaluate the antifungal effects of the nano-drug and compare the antifungal activity of these drugs with those of the common form of the fluconazole; the target was acquired.

Based on the results of the current study, fluconazole had high MIC against *Aspergillus* spp. Same results were reported by similar studies carried out by Fattahi et al. (20), Moore et al. (21), Messer et al. (22), and Sabatelli et al. (23). Filamentous fungi are usually not susceptible to fluconazole and MICs of this antibiotic against *Aspergillus* spp. are > 64 µg/mL (15). Fluconazole is a weak antifungal agent due to direct ligand bindings. Therefore, in addition to increasing azole resistance, *Aspergillus* spp. has inherent resistance to fluconazole (24). The main disadvantages of traditional methods were wastage of the medicine, adverse side effects related to doses, high cost of raw materials, and physicochemical incompatibilities. As a result, a part of the drug is excreted by the body without changes. In order to prevent and reduce such disadvantages, the pharmaceutical industries took a new stride toward the production and use of new systems for drug delivery. In the classical drug delivery systems, the medication is systemically administered in the body, and cells receive the drug from the blood based on their locations. The most important drug delivery systems are hydrogels, nano-fibers, and nano-liposomes, which are now subjected to extensive research (25).

In the current study, nano-liposomes were used in drug delivery. Lipids have low toxicity, but good lyophilization properties. Lipid nanoparticles as a drug delivery system increase chemical stability of the encapsulated drugs and allow controlled release of drugs. In addition, these systems are safe and secure carriers that can be easily produced on a large scale (26, 27). Further, Gupta et al. stated that the use of lipids increases penetration of fluconazole through the skin (28). The use of fluconazole-loaded nano-liposomes against resistant and sensitive species of *Candida* spp. showed better antifungal activities than the com-

Table 2. Results of Antifungal Susceptibility of *A. flavus* and *A. fumigatus* Isolates *in vitro* (n = 50)

Species/Antifungal Agent	MIC, $\mu\text{g/mL}$			
	MIC Range	MIC ₅₀	MIC ₉₀	GM
<i>A. flavus</i> (n = 25)				
Fluconazole	16 - 256	128	256	84.5
Nano-fluconazole	32	8 - 128	32	128
<i>A. fumigatus</i> (n = 25)				
Fluconazole	128 - 256	128	256	164.3
Nano-fluconazole	32 - 128	64	128	64

mon form of the drug (16). Use of nano-liposomes has many advantages, including improved penetration and diffusion of active ingredients, selective transport of active ingredients, longer release time, and greater stability of active ingredients (11). Nanoparticles increase bioavailability, solubility, and permeability, and can decrease drug dosage (29).

In the current study, the variables and parameters were modified as much as possible to obtain optimal fluconazole-loaded liposomal formulation. Dosage, lipid value, cholesterol value, and the ratio of drug to lipid are some of the variables involved in the production of liposomal formulations. It seems that the principal reason for the effectiveness of fluconazole-loaded nano-liposomes is the properties of nanoparticles that bring about change in the nature of matter at the nanoscale (25). With decrease in particle size, the number of molecules present at the surface of particle increases. Therefore, in a nanostructure, the surface ratio increases with respect to the volume (30). Further, increase of cholesterol in the lipid formulation allows more fluconazole to be encapsulated in nanoparticles, and brings about controlled and sustained release of loaded fluconazole; thereby, enhancing its chemical stability. Most probably this controlled release of medicine that allowed the continued effect of drug over a period of time reduced the expression of *CYP51A* gene in the isolates and broke the barrier of resistance, leading to a more effective drug.

6. Conclusions

Based on the results of the current study, further *in vitro* researches on the use of nano-drugs can help to introduce a new effective treatment with fewer side effects for patients with fungal lesions. This method can be useful to solve the problem of microbial resistance to commonly used antibiotics.

Footnotes

Authors' Contribution: Mohammad Reza Sarrafha: data collection, laboratory experiments, manuscript writing, and statistical analysis; Seyed Jamal Hashemi: project management, final approval of the study, and final editing of the manuscript; Sasan Rezaei and Mansour Bayat: scientific and practical consultants.

Funding/Support: There was no funding or financial support from any governmental or commercial organization for the present study.

References

- Sanz Alonso MA, Jarque Ramos I, Salavert Lleti M, Pemán J. Epidemiology of invasive fungal infections due to *Aspergillus* spp. and *Zygomycetes*. *Clin Microbiol Infect*. 2006;12:2-6. doi: [10.1111/j.1469-0691.2006.01602.x](https://doi.org/10.1111/j.1469-0691.2006.01602.x).
- Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis*. 2008;46(3):327-60. doi: [10.1086/525258](https://doi.org/10.1086/525258). [PubMed: 18177225].
- Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. *Lancet Infect Dis*. 2005;5(10):609-22. doi: [10.1016/S1473-3099\(05\)70238-3](https://doi.org/10.1016/S1473-3099(05)70238-3). [PubMed: 16183515].
- Seyedmousavi S, Guillot J, Arne P, de Hoog GS, Mouton JW, Melchers WJ, et al. *Aspergillus* and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. *Med Mycol*. 2015;53(8):765-97. doi: [10.1093/mmy/myv067](https://doi.org/10.1093/mmy/myv067). [PubMed: 26316211].
- Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. *Aspergillus flavus*: human pathogen, allergen and mycotoxin producer. *Microbiology*. 2007;153(Pt 6):1677-92. doi: [10.1099/mic.0.2007/007641-0](https://doi.org/10.1099/mic.0.2007/007641-0). [PubMed: 17526826].
- Leishangthem GD, Singh ND, Brar RS, Banga HS. Aspergillosis in avian species: A review. *J Poult Sci Technol*. 2015;3(1):1-14.
- Hagiwara D, Watanabe A, Kamei K. Sensitisation of an Azole-Resistant *Aspergillus fumigatus* Strain containing the *Cyp51A*-Related Mutation by Deleting the *Srba* Gene. *Sci Rep*. 2016;6:38833. doi: [10.1038/srep38833](https://doi.org/10.1038/srep38833). [PubMed: 27934927]. [PubMed Central: PMC5146965].
- Vermeulen E, Cooreman S, Maertens J, Jeurissen A, Lagrou K. Azole resistance in *Aspergillus*: an emerging problem? *Acta Clin Belg*. 2012;67(5):322-7. doi: [10.2143/ACB.67.5.2062684](https://doi.org/10.2143/ACB.67.5.2062684). [PubMed: 23189538].
- Mohammadi F, Hashemi SJ, Zoll J, Melchers WJ, Rafati H, Dehghan P, et al. Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-

- Positive *Aspergillus fumigatus* Isolates Obtained from Patients in Iran from 2010 to 2014. *Antimicrob Agents Chemother.* 2016;**60**(1):387-92. doi: [10.1128/AAC.02326-15](https://doi.org/10.1128/AAC.02326-15). [PubMed: [26525787](https://pubmed.ncbi.nlm.nih.gov/26525787/)]. [PubMed Central: [PMC4704245](https://pubmed.ncbi.nlm.nih.gov/PMC4704245/)].
10. Mellado E, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Role of *Aspergillus lentulus* 14- α sterol demethylase (Cyp51A) in azole drug susceptibility. *Antimicrob Agents Chemother.* 2011;**55**(12):5459-68. doi: [10.1128/AAC.05178-11](https://doi.org/10.1128/AAC.05178-11). [PubMed: [21947395](https://pubmed.ncbi.nlm.nih.gov/21947395/)]. [PubMed Central: [PMC3232793](https://pubmed.ncbi.nlm.nih.gov/PMC3232793/)].
 11. Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation and applications. *Int J Pharm Stud Res.* 2012;**3**(2):14-20.
 12. Venkateswarlu I, Jayashankar Reddy V, Ramesh Y, Viswanatha Reddy M, Pravallika CH, Suneetha KC. A Review on Liposomes. *RJPBCS.* 2011;**2**(3):739-51.
 13. Jenning V, Schafer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. *J Control Release.* 2000;**66**(2-3):115-26. [PubMed: [10742573](https://pubmed.ncbi.nlm.nih.gov/10742573/)].
 14. El-Nesr OH, Yahya SA, El-Gazayerly ON. Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes. *Saudi Pharm J.* 2010;**18**(4):217-24. doi: [10.1016/j.jsps.2010.07.003](https://doi.org/10.1016/j.jsps.2010.07.003). [PubMed: [23960730](https://pubmed.ncbi.nlm.nih.gov/23960730/)]. [PubMed Central: [PMC3730971](https://pubmed.ncbi.nlm.nih.gov/PMC3730971/)].
 15. Shinoda T. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. *Jpn J Med Mycol.* 1999;**40**:243-6.
 16. Asadi M, Hashemi JS, Hamishehkar H, Kordbacheh P, Ghasemi Z, Didehdar M, et al. In vitro evaluation of antifungal effects of nanoliposomal fluconazole against fluconazole susceptible and resistant *Candida* species isolated from patients. *Biosci Biotechnol Res Commun.* 2016;**9**(4):633-42.
 17. Tang X, Zhu H, Sun L, Hou W, Cai S, Zhang R, et al. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo. *Int J Nanomedicine.* 2014;**9**:5403-13. doi: [10.2147/IJN.S71623](https://doi.org/10.2147/IJN.S71623). [PubMed: [25473279](https://pubmed.ncbi.nlm.nih.gov/25473279/)]. [PubMed Central: [PMC4247144](https://pubmed.ncbi.nlm.nih.gov/PMC4247144/)].
 18. Zhang Y, Yang M, Portney NG, Cui D, Budak G, Ozbay E, et al. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. *Biomed Microdevices.* 2008;**10**(2):321-8. doi: [10.1007/s10544-007-9139-2](https://doi.org/10.1007/s10544-007-9139-2). [PubMed: [18165903](https://pubmed.ncbi.nlm.nih.gov/18165903/)].
 19. Honary S, Zahir F. Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 2). *Trop J Pharm Res.* 2013;**12**(2). doi: [10.4314/tjpr.v12i2.20](https://doi.org/10.4314/tjpr.v12i2.20).
 20. Fattahi A, Zaini F, Kordbacheh P, Hashemi SJ, Mahmoudi M, Safara M. In vitro susceptibility of aflatoxigenic and non-aflatoxigenic *Aspergillus flavus* strains to conventional antifungal agents. *Acta Med Iran.* 2012;**50**(12):798-804. [PubMed: [23456520](https://pubmed.ncbi.nlm.nih.gov/23456520/)].
 21. Moore CB, Sayers N, Mosquera J, Slaven J, Denning DW. Antifungal drug resistance in *Aspergillus*. *J Infect.* 2000;**41**(3):203-20. doi: [10.1053/jinf.2000.0747](https://doi.org/10.1053/jinf.2000.0747). [PubMed: [11120607](https://pubmed.ncbi.nlm.nih.gov/11120607/)].
 22. Messer SA, Jones RN, Fritsche TR. International surveillance of *Candida* spp. and *Aspergillus* spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). *J Clin Microbiol.* 2006;**44**(5):1782-7. doi: [10.1128/JCM.44.5.1782-1787.2006](https://doi.org/10.1128/JCM.44.5.1782-1787.2006). [PubMed: [16672407](https://pubmed.ncbi.nlm.nih.gov/16672407/)]. [PubMed Central: [PMC1479200](https://pubmed.ncbi.nlm.nih.gov/PMC1479200/)].
 23. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. *Antimicrob Agents Chemother.* 2006;**50**(6):2009-15. doi: [10.1128/AAC.00163-06](https://doi.org/10.1128/AAC.00163-06). [PubMed: [16723559](https://pubmed.ncbi.nlm.nih.gov/16723559/)]. [PubMed Central: [PMC1479149](https://pubmed.ncbi.nlm.nih.gov/PMC1479149/)].
 24. Warrilow AG, Melo N, Martel CM, Parker JE, Nes WD, Kelly SL, et al. Expression, purification, and characterization of *Aspergillus fumigatus* sterol 14- α demethylase (CYP51) isoenzymes A and B. *Antimicrob Agents Chemother.* 2010;**54**(10):4225-34. doi: [10.1128/AAC.00316-10](https://doi.org/10.1128/AAC.00316-10). [PubMed: [20660663](https://pubmed.ncbi.nlm.nih.gov/20660663/)]. [PubMed Central: [PMC2944604](https://pubmed.ncbi.nlm.nih.gov/PMC2944604/)].
 25. Vikaas B, Manjusha B, Manjusha C. Nanotechnology: Applications in pharmaceutical drug delivery systems. *J Chem Pharm Res.* 2016;**8**(8):259-65.
 26. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. *Adv Drug Deliv Rev.* 2001;**47**(2-3):165-96. [PubMed: [11311991](https://pubmed.ncbi.nlm.nih.gov/11311991/)].
 27. Bose S, Du Y, Takhistov P, Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. *Int J Pharm.* 2013;**441**(1-2):56-66. doi: [10.1016/j.ijpharm.2012.12.013](https://doi.org/10.1016/j.ijpharm.2012.12.013). [PubMed: [23262430](https://pubmed.ncbi.nlm.nih.gov/23262430/)].
 28. Gupta M, Tiwari S, Vyas SP. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. *Pharm Dev Technol.* 2013;**18**(3):550-9. doi: [10.3109/10837450.2011.598161](https://doi.org/10.3109/10837450.2011.598161). [PubMed: [21810069](https://pubmed.ncbi.nlm.nih.gov/21810069/)].
 29. Solano-Umana V, Vega-Baudrit JR, González-Paz R. The new field of the nanomedicine. *Int J Appl.* 2015;**5**(1).
 30. Subbenaik SC. Physical and chemical nature of nanoparticles. *Plant nanotechnology.* Springer; 2016.